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S20 Journal of Thoracic Oncology Vol. 11 No. 2S2) To test the hypothesis that SOX2 deregulation is a
key initiating event in the pathogenesis of bronchial
dysplasia
3) To deﬁne the functional impact of SOX2
deregulation
Methods: We use lentiviral transduction and Cas9/
CRISPR editing genome to genetically modify immor-
talized human bronchial epithelial cells (HBECs); thus
creating a suite of cells with complex genotypes,
recapitulating the molecular lesions seen in the human
disease. Genetically manipulated HBECs are grown at
the air-liquid interface on a stromal equivalent with
embedded pulmonary ﬁbroblasts – an organotypic
system (OTC). We use an inducible construct so that
SOX2 is only deregulated in HBECs that are already
conﬂuent at the air-liquid interface. OTCs are pro-
cessed for downstream analyses including immuno-
histochemistry, cell cycle analyses, RNA- Seq and
ChIP-Seq.
Results: We have developed a novel model that re-
capitulates human bronchial dysplasia. SOX2 deregula-
tion does not impact upon cell cycle progression or cell
population expansion in standard tissue culture condi-
tions. However, in the organotypic system described
above, overexpression of SOX2 in conﬂuent HBECs at the
air-liquid interface initiates focal dysplastic outgrowths
from the monolayer that exhibit histological character-
istics of high-grade human bronchial dysplasia.
Combining SOX2 activation with the loss of TP53
markedly potentiates the dysplastic phenotype, recapit-
ulating the likely in vivo sequence of molecular events.
SOX2 overexpression alters key cell signaling pathways
(MAPK and PI3K/AKT) in a pattern reﬂecting those seen
in squamous lung cancer.
Recent RNA- and CHiP-Seq analyses suggest SOX2
regulates a series of target genes implicated in cell
migration and metastasis, key hallmarks of malignant
progression. These results are currently being validated
and functional validation planned.
Conclusions: In the appropriate molecular and micro-
environmental context acute deregulation of SOX2 initi-
ates and drives bronchial dysplasia in immortalized
human bronchial epithelial cells. This work is consistent
with many others in which the microenvironment has
been shown to be as critical as cell intrinsic pathways in
the development of cancer.
This model system is well suited for screening novel
therapeutics and chemoprevention agents as well
advancing our understanding of the pathobiology of SQC.
Further work is underway to evaluate the functional
impact of SOX2 deregulation in this short-term model of
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Background: E74-like factor 3 (ELF3) is a member of
the ETS family of transcription factors that was recently
identiﬁed as an important target of SMAD4 in a mouse
model of lung tumorigenesis. ELF3 is also a described
oncogene in breast and prostate cancer; however, little is
known about the function of ELF3 in human lung cancer
and the dependence of ELF3 overexpression on SMAD4
loss. Here we investigate this dependence, as well as
alternative genetic and epigenetic mechanisms of ELF3
overexpression in two independent cohorts of lung
adenocarcinoma (AC).
Methods: DNA copy number, promoter methylation,
and mRNA expression data was queried in two co-
horts of lung AC: BC Cancer Research Centre (n¼83)
and The Cancer Genome Atlas (TCGA) (n¼551). Mu-
tation information was only available for the TCGA
cohort. GISTIC 2.0 was used to determine signiﬁcantly
focally ampliﬁed regions from segmentation data.
Stable shRNA knock-down of ELF3 was performed in a
panel of AC cell lines with high ELF3 expression.
Similarly, expression of ELF3 in HBECs was mediated
by lentiviral delivery of an overexpression vector. Cell
viability was assessed by MTT assay, while prolifera-
tion was assessed by BrdU assay and colony formation
assay. Tumor growth was monitored in vivo following
ﬂank injections of isogenic cell lines into NOD-SCID
mice. ELF3 cellular localization in lung AC cell lines
was assessed by western blot and immunoﬂuores-
cence, and in tumors by immunohistochemistry. As-
sociations with clinical features were determined by
Fisher’s tests, while survival analyses were performed
using the log-rank method.
Results: ELF3 overexpression occurred in over two-
thirds of lung adenocarcinomas and was not depen-
dent on SMAD4 copy number loss or underexpression.
In fact, tumors with high expression of ELF3 were
more likely to recur than those with SMAD4 loss
indicating divergent biological functions. ELF3 over-
expression was frequently selected-for at the DNA
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methylation occurring in 50-60% of tumors. Mutation
was not a frequent event. Importantly, the ELF3 locus
at 1q32.1 was focally ampliﬁed in 14.0% of tumors
(q value¼4.44E-05), compared to recently described
driver ampliﬁcations at MET (7.1%) and ERBB2
(8.2%). DNA-level selection of ELF3 was observed in
56% of tumors with no known driver, and was sta-
tistically enriched in KRAS mutant tumors and patients
who smoked. In vitro knock-down of ELF3 in AC cell
lines lead to signiﬁcantly reduced proliferation and
fewer colonies formed, while overexpression of ELF3
in HBECs lead to signiﬁcantly increased proliferation.
ELF3 overexpression alone was not sufﬁcient to
transform HBECs. In vivo, tumors with knock-down of
ELF3 displayed a trend towards decreased growth
over time (p¼0.08). ELF3 localization was found to be
nuclear in both cell lines and tumor specimens,
consistent with its function as a transcription factor.
Conclusions: Ampliﬁcation and hypomethylation of the
ELF3 locus is sufﬁcient to de-couple the dependence of
ELF3 overexpression on SMAD4 loss. Furthermore, ELF3
is a novel candidate oncogene on chromosome 1q, a
region that has remained “driverless” for some time.
Focal ampliﬁcation of ELF3 occurred at a higher fre-
quency than MET and ERBB2, recently described drivers
of lung AC, while additional DNA-level mechanisms of
selection occurred in over half of cases with no known
driver. Manipulation of ELF3 levels in cell models
demonstrated a clear role in the regulation of prolifer-
ation; further studies are warranted to determine the
potential of ELF3 as a pharmaceutical target.Detection of a novel RET gene fusion
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Introduction: In lung cancer, several driver Receptor
Tyrosine Kinases (RTKs) have been identiﬁed in gene
fusions, including ALK, RET, ROS1, NTRK1, NRG1 and
FGFR1/2/3. These oncogenic gene fusions have become
either direct targets or biomarkers for molecular ther-
apies for patients with lung cancer. Screening patients
for the presence of these gene fusions would be critical
for oncologists to select appropriate therapeutic
intervention or for drug developers to design noveltherapeutics and conduct clinical trials. However,
detection of fusions, especially unknown fusions, from
FFPE samples is challenging for many diagnostic tech-
niques. ArcherTM FusionPlexTM Lung Thyroid Panel is
built on Anchored Multiplex PCR (AMPTM) Chemistry,
allowing detection of both novel and known fusions.
Here we report the results from our study using the
Archer Lung-Thyroid Panel. We identiﬁed and veriﬁed
the presence of a novel fusion between Myosin Phos-
phatase Rho Interacting Protein (MPRIP) and RET
oncogene, in an FFPE sample from a non-small cell lung
cancer (NSCLC) patient.
Methods: FFPE samples from 20 NSCLC patients
were analyzed in the study. An RNA sample con-
taining an ALK and ROS1 fusion was used as the
positive control, and FFPE processed GM12878 was
used as the negative control. In addition, FFPE con-
trols containing TMP3-NTRK1 and CCDC6-RET were
also used to evaluate the performance of the panel to
detect fusions. Total nucleic acid (TNA) was extrac-
ted from the FFPE sections using the AgencourtTM
FORMAPURETM kit. For each sample, 200 ng of TNA
was used for library preparation. The barcoded
libraries from 14 samples were pooled and
sequenced on an Illumina MiSeq using a v2 ﬂow cell.
The FASTA ﬁles from the MiSeq were then analyzed
by the ArcherDX data analysis pipeline to determine
the presence of gene fusions with driver genes
including ALK, FGFR3, MET, NTRK1, NTRK3, NTRK3,
PPARG, RET, and ROS1. The detected fusions in
clinical samples were further conﬁrmed by Sanger
sequencing and FISH.
Results: The known fusions, including EM4-ALK,
SLC34A2-ROS1, TMP3-NTRK1, and CCDC6-RET were
successfully detected in the positive RNA and FFPE
control samples. For all of the clinical FFPE samples,
one 10 micron section was sufﬁcient to yield more
than the required 200 ng TNA for library preparation.
Although three of the twenty (15%) FFPE samples
failed the initial sample quality metrics, libraries were
prepared for all 20 NCSLC FFPE samples and
sequenced on MiSeq. Among the three samples that
did not pass the initial sample QC, two of them also
failed the QC metrics for fusion detection. From the
seventeen samples that did pass the initial QC, one
sample failed the fusion QC. Overall, the success rate
for the clinical samples tested with this panel was
85%. Among the 20 NSCLC samples, one sample was
found to harbor a novel, in-frame fusion between exon
19 of MPRIP and exon 12 of RET. This type of fusion
would retain an intact kinase domain (exons 12-18) of
RET, and would presumably be oncogenic. Using
the RNA portion of the TNA extracted, cDNA was
